Scientific Publications
- PMID: 20153888
- Title: Daily acyclovir for HIV 1 disease progression in people dually infected with HIV 1 and herpes simplex virus type 2 a randomised placebo controlled trial
- Abstract: Most people infected with HIV-1 are dually infected with herpes simplex virus type 2. Daily suppression of this herpes virus reduces plasma HIV-1 concentrations, but whether it delays HIV-1 disease progression is unknown. We investigated the effect of acyclovir on HIV-1 progression.
- Date: 1970-08-21
- Year: 2010
- Journal: Lancet
- PMID Author: Lingappa JR, Baeten JM, Wald A, Hughes JP, Thomas KK, Mujugira A, Mugo N, Bukusi EA, Cohen CR, Katabira E, Ronald A, Kiarie J, Farquhar C, Stewart GJ, Makhema J, Essex M, Were E, Fife KH, de Bruyn G, Gray GE, McIntyre JA, Manongi R, Kapiga S, Coetzee D, Allen S, Inambao M, Kayitenkore K, Karita E, Kanweka W, Delany S, Rees H, Vwalika B, Magaret AS, Wang RS, Kidoguchi L, Barnes L, Ridzon R, Corey L, Celum C
- PMC Link #: PMC2877592
Daily acyclovir for HIV 1 disease progression in people dually infected with HIV 1 and herpes simplex virus type 2 a randomised placebo controlled trial
Daily acyclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomised placebo-controlled trial. Lancet 2010;375(9717):824-33 doi: 10.1016/S0140-6736(09)62038-9
Media Contacts
North America
Rose Catlos
+1 212 847 1049
RCatlos@iavi.org
